Top 10 Most Expensive Drugs in the World in 2026
The pharmaceutical industry has developed advanced medicines to treat rare genetic diseases and serious health conditions. However, some of these treatments come with extremely high price tags, sometimes costing millions of dollars per patient.
Gene therapies such as Lenmeldy, Hemgenix, and Elevidys are among the most expensive treatments in the world. Many are designed to address the underlying cause of a disease and may provide long-term benefits through a single treatment.
The high cost of these medicines is mainly due to years of research, clinical trials, advanced technology, and complex manufacturing. Since many rare diseases affect only a small number of people, these development costs are spread across fewer patients, making each treatment more expensive.
In this article, we explore the 10 most expensive medicines in the world, their uses, manufacturers, and treatment costs, including both one-time therapies and medicines requiring annual treatment.
1. Lenmeldy
| Information | Details |
|---|---|
| Price | About $4.25 million per treatment |
| Disease Treated | Metachromatic leukodystrophy (MLD), a rare inherited disorder that damages the nervous system |
| Drug Type | Gene therapy (uses the patient’s own stem cells) |
| Manufacturer | Orchard Therapeutics |
| Approval Year | 2024 |
Lenmeldy (atidarsagene autotemcel) is a one-time gene therapy developed to treat children with metachromatic leukodystrophy (MLD), a rare and potentially life-threatening genetic disorder affecting the nervous system. Developed by Orchard Therapeutics, now part of Kyowa Kirin, Lenmeldy received US FDA approval in March 2024. It is indicated for children with specific early-onset forms of MLD.
MLD is caused by changes in the ARSA gene, resulting in a deficiency of the arylsulfatase A enzyme. This causes fatty substances called sulfatides to accumulate and damage the myelin sheath, the protective covering around nerve cells. As the disease progresses, affected children can lose important abilities such as walking, speaking, swallowing, and seeing.
Lenmeldy uses the patient's own blood-forming stem cells, which are collected and modified outside the body to carry a functional copy of the ARSA gene. These cells are then infused back into the patient, helping the body produce the missing enzyme. The treatment is administered as a single infusion following preparatory procedures at specialized treatment centers.
The treatment had a reported US wholesale acquisition cost (WAC) of US$4.25 million per treatment when its US launch was announced in March 2024, making it the most expensive medicine in the US at that time. Its high price reflects several factors, including advanced gene therapy technology, personalised cell manufacturing, extensive research and development, and the relatively small number of eligible patients. The manufacturer also highlighted its potential long-term value for patients, families, caregivers, and healthcare systems.
The US$4.25 million figure represents the announced US wholesale acquisition cost, not necessarily the final amount paid by the patient.
2. Hemgenix: A One-Time Gene Therapy for Hemophilia B
| Information | Details |
|---|---|
| Price | About $3.5 million per dose (£2.6 million in the UK) |
| Disease Treated | Hemophilia B, a lifelong bleeding disorder |
| Drug Type | Gene therapy (single IV infusion) |
| Manufacturer | CSL Behring (developed with uniQure) |
| Approval Year | 2022 |
Hemgenix (etranacogene dezaparvovec-drlb) is a gene therapy approved for adults with haemophilia B, a rare inherited bleeding disorder caused by insufficient production of factor IX, a protein needed for normal blood clotting. People with this condition may experience repeated bleeding episodes, particularly in their joints and muscles. Traditionally, managing haemophilia B requires regular factor IX replacement infusions, sometimes throughout a person's life.
Hemgenix is designed to address the underlying cause of the condition through a single intravenous infusion. It uses an adeno-associated virus type 5 (AAV5) vector to deliver genetic instructions to liver cells, helping them produce factor IX. This may reduce bleeding episodes and the need for ongoing factor IX replacement treatment in eligible patients. The genetic material generally remains separate from the patient's own DNA.
Hemgenix received a reported US wholesale acquisition cost (WAC) of US$3.5 million per treatment when it was launched in 2022, placing it among the world's most expensive medicines. In the UK, its list price is £2.6 million per treatment, according to the National Institute for Health and Care Excellence (NICE). The high cost reflects advanced gene therapy technology, research and development investment, specialised manufacturing, and the relatively small patient population. Its potential to reduce the need for repeated factor IX replacement treatments is also considered when assessing its long-term value.
3. Elevidys: A Gene Therapy for Duchenne Muscular Dystrophy
| Information | Details |
|---|---|
| Price | About $3.2 million per dose |
| Disease Treated | Duchenne muscular dystrophy (DMD) |
| Drug Type | Gene therapy (single IV infusion) |
| Manufacturer | Sarepta Therapeutics |
| Approval Year | 2023 |
Elevidys (delandistrogene moxeparvovec-rokl) is a gene therapy developed by Sarepta Therapeutics to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle weakness and damage. It uses an adeno-associated virus (AAV) vector to deliver genetic instructions that help the body produce a shortened form of dystrophin, a protein that supports muscle function.
Administered as a single intravenous infusion, Elevidys was initially approved in the United States in June 2023 for eligible paediatric patients with DMD. Its reported launch price was approximately US$3.2 million per treatment, placing it among the most expensive gene therapies. The high price reflects years of research and clinical development, specialised manufacturing, advanced gene delivery technology, and the relatively small number of patients eligible for treatment.
Elevidys also requires careful patient selection and medical monitoring. Its prescribing information includes a boxed warning for acute serious liver injury, including potentially life-threatening liver failure. Other important safety concerns include infusion-related reactions, immune-mediated myositis, and myocarditis. Treatment eligibility and precautions depend on the current prescribing information and the patient's medical condition.
The US$3.2 million figure refers to its reported initial US launch price; actual treatment costs and access arrangements may vary.
4. Skysona: A Gene Therapy for Cerebral Adrenoleukodystrophy
| Information | Details |
|---|---|
| Price | About $3 million per treatment |
| Disease Treated | Early, active cerebral adrenoleukodystrophy (CALD) in boys aged 4–17 |
| Drug Type | Gene therapy (uses the patient’s own stem cells) |
| Manufacturer | bluebird bio (now Genetix Biotherapeutics) |
| Approval Year | 2022 |
Skysona (elivaldogene autotemcel) is a gene therapy developed to slow the progression of neurological damage in boys aged 4–17 with early, active cerebral adrenoleukodystrophy (CALD). This rare inherited disorder affects the brain and nervous system and is caused by mutations in the ABCD1 gene, which prevent the body from producing a functional adrenoleukodystrophy protein (ALDP). Without this protein, very long-chain fatty acids accumulate and damage the myelin sheath that protects nerve cells, potentially leading to severe neurological disability.
Skysona is made using the patient's own blood-forming stem cells. These cells are collected and modified to carry a functional copy of the gene responsible for producing ALDP. They are then infused back into the patient as a one-time intravenous treatment. Clinical study results showed an estimated 72% likelihood of remaining free from major functional disability at 24 months among treated patients, compared with 43% in untreated patients.
Skysona had a reported US treatment price of approximately US$3 million per dose, making it one of the most expensive gene therapies. Its high cost reflects specialised cell collection and manufacturing, advanced gene-modification technology, extensive clinical research, and the limited number of eligible patients.
However, Skysona carries an important boxed warning for blood cancers, including myelodysplastic syndrome and acute myeloid leukaemia. Other safety concerns include serious infections and blood-cell complications. Treatment requires careful patient selection and long-term medical monitoring.
Note: Skysona's US indication received accelerated approval, and its use is subject to specific eligibility requirements and safety precautions. The reported US$3 million price is an approximate treatment price, not necessarily the final amount paid by patients or healthcare systems.
5. Zynteglo: A Gene Therapy for Transfusion-Dependent Beta-Thalassemia
| Information | Details |
|---|---|
| Price | About $2.8 million per treatment |
| Disease Treated | Beta-thalassemia needing regular blood transfusions |
| Drug Type | Gene therapy (uses the patient’s own stem cells) |
| Manufacturer | bluebird bio |
| Approval Year | 2022 |
Zynteglo (betibeglogene autotemcel) is a one-time gene therapy developed by bluebird bio to treat adults and children with beta-thalassemia who require regular red blood cell transfusions. Beta-thalassemia is an inherited blood disorder that affects haemoglobin production and can cause severe anaemia. Many patients depend on regular blood transfusions, sometimes every two to five weeks, to manage the condition.
Zynteglo uses the patient's own blood-forming stem cells, which are collected and modified outside the body using a lentiviral vector. The process introduces functional copies of a modified beta-globin gene, helping the body produce healthy haemoglobin. Following the modification, the cells are infused back into the patient as a single intravenous treatment. For eligible patients, this may reduce or eliminate the need for regular red blood cell transfusions.
Zynteglo had a reported US wholesale acquisition cost of approximately US$2.8 million per treatment when it was launched in 2022. Its high price reflects advanced gene therapy technology, personalised cell collection and manufacturing, extensive research and clinical development, and the relatively small number of eligible patients.
The treatment also requires specialised medical care, including preparatory conditioning and monitoring for potential side effects. As with other gene therapies, treatment eligibility and safety considerations must be assessed by qualified healthcare professionals. The reported US$2.8 million is the initial US list price and may differ from the final amount paid by patients or healthcare systems.
6. Zolgensma: A One-Time Gene Therapy for Spinal Muscular Atrophy
| Information | Details |
|---|---|
| Price | About $2.1 million per dose |
| Disease Treated | Spinal muscular atrophy (SMA) in children under 2 |
| Drug Type | Gene therapy (single IV infusion) |
| Manufacturer | Novartis |
| Approval Year | 2019 |
Zolgensma (onasemnogene abeparvovec-xioi) is a gene therapy developed by Novartis to treat spinal muscular atrophy (SMA), a rare genetic disorder that affects motor neurons and causes progressive muscle weakness. It is approved in the United States for children under two years of age with specific mutations in both copies of the SMN1 gene. SMA occurs when the body cannot produce enough survival motor neuron (SMN) protein to support the normal function of motor neurons.
Zolgensma addresses the underlying genetic cause by delivering a functional copy of the SMN1 gene to help the body produce the missing SMN protein. It is administered as a single intravenous (IV) infusion, rather than requiring repeated doses like some conventional SMA treatments. At its US approval in 2019, the treatment was priced at approximately US$2.125 million, making it one of the most expensive medicines in the world. In India, the reported cost has been around ₹16–17 crore per dose, largely because the treatment is imported.
The high price reflects several factors, including advanced gene therapy technology, extensive research and development, specialised manufacturing processes, and the small number of eligible patients. Although it can significantly improve outcomes, Zolgensma is not suitable for every patient, and its long-term effects require continued medical monitoring.
Key points about Zolgensma:
- Manufacturer: Novartis
- Generic name: Onasemnogene abeparvovec-xioi
- Condition treated: Spinal muscular atrophy (SMA)
- Administration: One-time intravenous infusion
- Reported US price at approval: Approximately US$2.125 million
- Reported price in India: Around ₹16–17 crore per dose
Important limitations: The safety and effectiveness of repeat administration have not been established. Its use in patients with advanced SMA, such as those with complete limb paralysis or permanent ventilator dependence, has also not been evaluated. Zolgensma is not a guaranteed cure, and treatment decisions require specialist assessment and monitoring.
7. Zokinvy: A Treatment for Rare Premature Ageing Disorders
| Information | Details |
|---|---|
| Price | About $1.0–1.2 million per year |
| Disease Treated | Progeria and progeroid laminopathies (rare premature-aging disorders) |
| Drug Type | Oral capsule (farnesyltransferase inhibitor) |
| Manufacturer | Eiger BioPharmaceuticals |
| Approval Year | 2020 |
Zokinvy (lonafarnib) is an oral medicine developed to reduce the risk of early death in people with Hutchinson-Gilford Progeria Syndrome (HGPS), commonly known as progeria, and certain processing-deficient Progeroid Laminopathies. These are extremely rare genetic conditions that cause premature ageing and can lead to serious health complications, particularly cardiovascular problems.
Zokinvy works by blocking an enzyme called farnesyltransferase, which helps prevent the abnormal processing and accumulation of progerin, a protein associated with progeria. It is approved for adults and children aged 12 months and older who meet specific body-surface-area and genetic criteria. Clinical evidence has shown a survival benefit, with treatment helping eligible patients live longer than those who did not receive it. The medicine is taken orally twice daily, making it a continuing treatment rather than a one-time therapy.
The annual treatment cost has been reported at approximately US$1.03 million, reflecting the complexity of developing medicines for extremely rare genetic conditions, specialised research, and the limited number of patients who need treatment.
Key points about Zokinvy:
- Generic name: Lonafarnib
- Condition treated: Hutchinson-Gilford Progeria Syndrome and certain processing-deficient Progeroid Laminopathies
- Manufacturer: Originally developed by Eiger BioPharmaceuticals
- Administration: Oral medicine taken twice daily
- Minimum age: 12 months, subject to specific eligibility criteria
- Reported annual treatment cost: Approximately US$1.03 million
Zokinvy is not approved for all forms of progeroid syndromes or processing-proficient Progeroid Laminopathies. Its use is limited to patients who meet the approved genetic and clinical criteria.
8. Myalept: A Treatment for Generalized Lipodystrophy
| Information | Details |
|---|---|
| Price | About $0.9–1.3 million per year (sources differ) |
| Disease Treated | Complications of leptin deficiency in generalized lipodystrophy |
| Drug Type | Biologic (daily injection under the skin) |
| Manufacturer | Chiesi Farmaceutici |
| Approval Year | 2014 |
Myalept (metreleptin) is a prescription medicine approved by the US FDA to treat complications caused by leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Lipodystrophy is a rare condition that affects how the body stores and distributes fat. People with generalized lipodystrophy may develop severe insulin resistance, diabetes and high triglyceride levels, which can increase the risk of pancreatitis.
Myalept works as a replacement for leptin, a hormone normally produced by fat tissue that helps regulate metabolism. It is used alongside a prescribed diet and administered as a subcutaneous injection once daily. Patients or caregivers can be trained to give the injection at home. Since the dosage is based on body weight, the number of vials required varies between patients. Reported annual treatment costs range from approximately US$890,000 to more than US$1.3 million, depending on the dosage and monthly vial requirements.
The high price is associated with the rarity of the condition, specialised biotechnology manufacturing, research and development expenses, and the limited number of patients requiring treatment.
Key points about Myalept:
- Generic name: Metreleptin
- Condition treated: Complications of congenital or acquired generalized lipodystrophy
- Administration: Once-daily subcutaneous injection
- Treatment approach: Used alongside a prescribed diet
- Reported annual treatment cost: Approximately US$890,000 to over US$1.3 million, depending on dosage and vial requirements
Important note: Myalept is not indicated for treating general obesity or other forms of lipodystrophy. It requires medical supervision because of important safety considerations, including the risk of neutralising antibodies and lymphoma. Actual treatment costs may vary by country, dosage and healthcare coverage.
9. Luxturna
| Information | Details |
|---|---|
| Price | About $850,000 for both eyes |
| Disease Treated | Inherited retinal dystrophy caused by RPE65 gene mutations |
| Drug Type | Gene therapy (injected into the eye) |
| Manufacturer | Spark Therapeutics |
| Approval Year | 2017 |
Luxturna (voretigene neparvovec) is a gene therapy developed by Spark Therapeutics to treat inherited retinal dystrophy caused by mutations in both copies of the RPE65 gene (biallelic RPE65-mediated inherited retinal dystrophy). It was the first gene therapy approved in the United States for an inherited disease. The treatment is intended for eligible adults and children who experience vision loss due to this rare genetic condition, which can eventually lead to blindness.
Luxturna is administered as a one-time treatment through an injection into the eye (intraocular administration). The procedure takes place in a controlled hospital setting and must be performed by an experienced eye surgeon. Patients also receive immunosuppressive medicines for a few days before treatment to reduce the risk of an unwanted immune response.
With an estimated price of $850,000 for treatment of both eyes, Luxturna is among the world's most expensive medicines. However, because it is designed as a one-time treatment rather than requiring ongoing doses, its overall cost may be lower than that of some treatments that need repeated administration.
Why Is Luxturna So Expensive?
Luxturna's high price is associated with several factors:
- Advanced gene therapy technology: It uses specialized technology to deliver a functional copy of the RPE65 gene to retinal cells.
- Rare disease treatment: It is developed for a specific inherited condition that affects a relatively small patient population.
- High research and development costs: Developing gene therapies requires extensive scientific research, clinical studies, and specialized expertise.
- Complex manufacturing: Production involves sophisticated processes, specialized laboratory facilities, and strict quality controls.
- Specialized administration: The treatment requires a controlled clinical environment and an experienced eye surgeon.
10. Soliris
| Information | Details |
|---|---|
| Price | About $470,000–700,000 per year (varies by source and condition) |
| Disease Treated | PNH, atypical HUS, generalized myasthenia gravis and NMOSD |
| Drug Type | Monoclonal antibody (IV infusion) |
| Manufacturer | Alexion Pharmaceuticals (AstraZeneca) |
| Approval Year | 2007 |
Soliris (eculizumab), originally developed by Alexion Pharmaceuticals, which is now part of AstraZeneca, is a monoclonal antibody medicine used to treat several rare and serious conditions. These include paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease.
NMOSD is an autoimmune condition that can cause inflammation and damage to the optic nerves and spinal cord. Soliris helps control the abnormal immune response associated with these conditions.
The medicine is administered through an intravenous infusion by a healthcare professional. Its annual list price is approximately $470,000, although some sources report figures exceeding $678,000 per year, depending on the pricing period and market growth.
Read also: 10 Factors Affecting Pharmaceutical Prices and How to Manage Them
Source Reference Sites
Conclusion
The rising cost of medicines reflects the research, advanced technology, and specialized manufacturing required to develop treatments for serious and rare diseases. While these medicines offer new possibilities for patients, affordability and global accessibility remain important challenges.
As a growing name in the pharmaceutical industry, Malambi Healthcares supports the distribution of quality medicines to international markets. With its focus on global healthcare needs, the company aims to strengthen its position as a pharmaceutical exporter in India. Contact Malambi Healthcares to learn more about its pharmaceutical export solutions.
Disclaimer: This article has been prepared based on available research and publicly accessible information. Drug prices and dosage requirements may vary depending on the country, healthcare system, and individual treatment needs. The figures mentioned are approximate and may contain unintentional errors or omissions. Readers are encouraged to verify the details with official sources or qualified healthcare professionals. If any inaccuracies or discrepancies are identified, we welcome feedback and will make reasonable efforts to review and correct them.